Dr. Eden has been the CEO of MeMed since its inception in 2009, leading it from an idea to a rapidly growing company. He has 14 years of combined business and academic experience leading the development of cutting-edge multidisciplinary technologies that synergize molecular biology and informatics. Dr. Eden co-founded several highly funded international consortia (e.g., Tailored-Treatment, Respiratory-ImmunoDx, AutoPilotDx), the mission of which is to develop, clinically validate and commercialize novel technologies for diagnosing patients with infectious diseases and inflammatory disorders. He holds a B.Sc. in Computer Engineering, B.A. in Biology, and M.Sc. in Computer Science (all Cum Laude) from the Technion, Israel Institute of Technology, and a Ph.D. in Systems Biology from the Weizmann Institute of Science. Dr. Eden is co-author of over 20 patents and 17 peer-reviewed publications, and is the recipient of multiple awards including the prestigious GE and Science Prize for Promising Life Scientists.  

Dr. Oved has 13 years of combined industry and academic experience, leading interdisciplinary projects that apply molecular immunology-based technologies to clinical applications. Dr. Oved holds a B.A. in Biology (Summa Cum Laude), B.Sc. in medicine (Magna Cum Laude), Ph.D. in molecular immunology, and M.D. from the Medical School at the Technion, Israel Institute of Technology. He served as scientific advisor at Applied Immune Technologies (AIT) Inc., is co-author of 15 patents and 10 peer-reviewed publications, and is the recipient of multiple awards including the prestigious Wolf Award for research students.
*Subject to completing a trainee period.

Mr. Terry is a social entrepreneur who has co-founded a dozen life science organizations in the last 20 years and has been called the godfather of applied genomics and personalized medicine. The organizations co-founded by Mr. Terry include innovative philanthropic, research, and commercial organizations based on the life sciences, applied technology, and social-network theory. In 2000, he co-founded Genomic Health, Inc. (NASDAQ: GHDX), a pioneering personalized medicine company. Mr. Terry has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery all over the world. He has received many honors and awards in the business and scientific communities internationally. He has dedicated his career to advancing a patient-centered perspective in research, product development, and translational medicine. He is active internationally with strategic management and financing of stratified medicine companies for numerous clinical indications and technologies.

Mr. Halbreich has over 15 years of professional experience in global operations, business development, strategic planning and M&As. Prior to joining MeMed’s team, Mr. Halbreich led the global operations activity of MediaMind Technologies Inc., and following its purchase by Digital Generation Inc. (Nasdaq: DGIT), led the global operations integration process of the companies. Prior to that, Mr. Halbreich was the COO of Neuronix Medical, an innovative medical device company in the field of Alzheimer’s disease treatment. Before that, Mr. Halbreich acted as VP of Business Development & Legal Counsel for Office Depot (Israel). Mr. Halbreich also served as a commercial lawyer for some of Israel’s most prominent law firms, handling large-scale commercial activities including M&A, joint ventures, licensing and investment agreements. Mr. Halbreich holds an LLB from the Hebrew University of Jerusalem and an MBA (Finance) from the Interdisciplinary Center in Herzliya.

Dr. Gottlieb has over 20 years of experience in academia and biotech, specializing in building international collaborations and securing non-dilutive financing. Before joining MeMed, Dr. Gottlieb was Director of Business Development at BiondVax Pharmaceuticals Ltd (NASDAQ: BVXV), an innovative developer of a universal influenza vaccine. Dr. Gottlieb holds a BA in Natural Sciences and PhD from Cambridge University, UK and an MBA from the Technion – Institute of Technology, Israel. Between completing her doctorate and entering biotech, Dr. Gottlieb was a postdoctoral fellow at the Weizmann Institute of Science, Israel and the Fred Hutchinson Cancer Research Center in Seattle, WA, USA. In 2004 Dr. Gottlieb founded Gottlieb Scientific Communications, a scientific writing and editing company, which she has run for the past 10 years. Dr. Gottlieb is co-author of over 20 peer reviewed publications and the recipient of multiple awards, including the Royal Society (UK)-Israel Academy Postdoctoral Fellowship.